CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 corresponding to amino acids 148-156 of the BRLF1 protein. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters.
CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 is a synthetic peptide corresponding to amino acids 148 through 156 of the BRLF-1 protein from the Epstein-Barr Virus (EBV). As a well-characterized, immunodominant epitope, it is widely recognized for its role in the study of viral lytic cycle regulation and immune system interactions with EBV-infected cells. The sequence represents a key region involved in T cell recognition, making it an important reagent for immunological assays, viral pathogenesis research, and the development of diagnostic platforms focused on EBV-associated disorders. Its defined structure and relevance to viral reactivation events position it as a valuable tool for both basic and applied research in virology and immunobiology.
Epitope mapping: Researchers commonly employ this peptide in epitope mapping studies to identify and characterize T cell responses specific to the BRLF-1 protein during EBV infection. By presenting the defined 148-156 sequence to immune cells, scientists can dissect the specificity and magnitude of cytotoxic T lymphocyte (CTL) recognition, facilitating a deeper understanding of host-pathogen interactions and the immune surveillance mechanisms that control EBV reactivation and persistence.
Immunomonitoring: The peptide is frequently utilized in immunomonitoring protocols to assess EBV-specific cellular immune responses in peripheral blood mononuclear cells (PBMCs) or isolated T cell populations. Through ex vivo stimulation assays such as ELISPOT or intracellular cytokine staining, investigators can quantify the frequency and functionality of BRLF-1-specific T cells, supporting studies on immune competence, viral latency, and the dynamics of cellular immunity in both healthy and immunocompromised individuals.
Peptide-MHC binding assays: As a defined class I MHC-restricted epitope, the BRLF-1 148-156 peptide is instrumental in peptide-MHC binding studies. It enables the evaluation of peptide affinity for various HLA alleles, supporting research into antigen processing, presentation, and the molecular determinants of T cell recognition. These assays contribute to the optimization of immunotherapeutic strategies and the design of peptide-based immunodiagnostics targeting EBV.
Vaccine research: The sequence serves as a model antigen for preclinical vaccine development targeting EBV lytic proteins. By incorporating this peptide into experimental immunization protocols, researchers can assess its immunogenicity, optimize adjuvant formulations, and evaluate the induction of protective T cell responses in vitro and in vivo. Such studies are foundational for advancing prophylactic and therapeutic vaccine candidates against EBV-associated diseases.
Assay development: The BRLF-1 148-156 peptide is a valuable component in the development and validation of immunological assays, including tetramer staining reagents, cytotoxicity assays, and high-throughput screening platforms. Its use enables precise quantification and functional analysis of epitope-specific T cells, supporting translational research efforts and quality control processes in immunology laboratories focused on EBV research.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More